Company research
Nyxoah SA
CIK 1857190Updated Nov 6, 2026
SecurityNYXH · NASDAQ · equity
NYXH price & chart
Loading TradingView…
NASDAQ:NYXH on TradingView ↗About the company
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · EURSource
Source
Source
cash flow · annual statements
| Line item | Q4 2022 | Q4 2021 | Q3 2022 | Q3 2021 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossEUR | — | — | -6,240,000Source | -8,762,000Source | -20,607,000Source | -13,124,000Source | -12,797,000Source | -4,990,000Source | -90,085,000Source | -59,236,000Source | -43,212,000Source | -31,225,000Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForCurrentTaxOfPriorPeriodEUR | — | — | — | — | — | — | — | — | 14,000Source | -152,000Source | -1,622,000Source | 0Source |
| AdjustmentsForDepreciationAndAmortisationExpenseAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossEUR | — | — | — | — | — | — | — | — | 2,254,000Source | — | — | — |
| AdjustmentsForFinanceCostsEUR | — | — | — | — | — | — | — | — | 11,519,000Source | 5,070,000Source | 3,729,000Source | 4,320,000Source |
| AdjustmentsForFinanceIncomeEUR | — | — | — | — | — | — | — | — | 5,928,000Source | 7,447,000Source | 4,174,000Source | 6,763,000Source |
| AdjustmentsForSharebasedPaymentsEUR | — | — | — | — | — | — | — | — | 4,886,000Source | 3,968,000Source | 2,611,000Source | 2,698,000Source |
| InterestPaidClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | — | — | 694,000Source | 496,000Source | 192,000Source | 130,000Source |
| InterestReceivedClassifiedAsOperatingActivitiesEUR | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 3,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | — | — | 1,133,000Source | 1,208,000Source | 757,000Source | 772,000Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | — | — | — | 10,000,000Source | — | 0Source |
| ProceedsFromIssuingSharesEUR | — | — | — | — | — | 45,600,000Source | — | — | 20,864,000Source | 69,722,000Source | 18,337,000Source | 255,000Source |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesEUR | — | — | — | — | — | — | — | — | 3,000Source | 7,000Source | — | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesEUR | — | — | — | — | — | — | — | — | 2,964,000Source | 4,907,000Source | 8,462,000Source | 15,463,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | — | — | — | — | — | — | — | — | — | 63,000Source | 83,000Source | 83,000Source |
income statement · annual statements
| Line item | Q4 2022 | Q4 2021 | Q3 2022 | Q3 2021 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Selling, General and Administrative ExpenseEUR | — | — | 4,763,000Source | 4,496,000Source | 10,672,000Source | 6,383,000Source | 6,185,000Source | 4,536,000Source | 48,261,000Source | 28,461,000Source | 21,687,000Source | 18,855,000Source |
| Total Revenue | — | — | — | — | — | — | — | — | — | — | — | — |
| Additional Financial Items | ||||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | 0.25Source | 0.25Source | 0.25Source | 0.25Source |
| AverageEffectiveTaxRatenumber | — | — | — | — | — | — | — | — | -0.01Source | -0.05Source | 0.03Source | -0.04Source |
| BasicEarningsLossPerShareEUR/shares | — | — | -0.24Source | -0.35Source | -0.55Source | -0.43Source | -0.45Source | -0.19Source | -2.36Source | -1.81Source | -1.55Source | -1.21Source |
| CurrentTaxExpenseIncomeEUR | — | — | 944,000Source | 136,000Source | 275,000Source | 434,000Source | 927,000Source | 944,000Source | 1,026,000Source | 2,811,000Source | -1,442,000Source | 1,179,000Source |
| DeferredTaxExpenseIncomeEUR | — | — | -879,000Source | — | 3,000Source | 7,000Source | 1,000Source | -837,000Source | -31,000Source | -7,000Source | -3,000Source | -10,000Source |
| DepreciationRightofuseAssetsEUR | — | — | — | — | — | — | — | — | 1,200,000Source | 1,000,000Source | 800,000Source | — |
| DilutedEarningsLossPerShareEUR/shares | — | — | -0.24Source | -0.35Source | -0.55Source | -0.43Source | -0.45Source | -0.19Source | -2.36Source | -1.81Source | -1.55Source | -1.21Source |
| EmployeeBenefitsExpenseEUR | — | — | 4,647,000Source | 3,576,000Source | 10,026,000Source | 5,536,000Source | — | — | 40,741,000Source | 23,783,000Source | — | — |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | — | — | 845,000Source | 784,000Source | 887,000Source | 540,000Source | — | — | 4,886,000Source | 3,968,000Source | — | — |
| ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsedEUR | — | — | — | — | — | — | — | — | 198,000Source | 135,000Source | 202,000Source | 240,000Source |
| FinanceCostsEUR | — | — | 2,524,000Source | 585,000Source | 3,337,000Source | 1,445,000Source | 775,000Source | 2,162,000Source | 11,519,000Source | 5,070,000Source | 3,729,000Source | 4,320,000Source |
| FinanceIncomeEUR | — | — | 5,127,000Source | 29,000Source | 2,858,000Source | 2,069,000Source | 789,000Source | 4,669,000Source | 5,928,000Source | 7,447,000Source | 4,174,000Source | 6,763,000Source |
| GrossProfitEUR | — | — | 119,000Source | 121,000Source | 850,000Source | 490,000Source | 688,000Source | 602,000Source | 6,326,000Source | 2,969,000Source | 2,692,000Source | 1,934,000Source |
| IncomeTaxExpenseContinuingOperationsEUR | — | — | 65,000Source | 136,000Source | 278,000Source | 441,000Source | 928,000Source | 107,000Source | 1,009,000Source | 2,804,000Source | -1,445,000Source | 1,169,000Source |
| InterestExpenseOnLeaseLiabilitiesEUR | — | — | 26,000Source | 22,000Source | 35,000Source | 36,000Source | 30,000Source | 25,000Source | 121,000Source | 150,000Source | 129,000Source | 98,000Source |
| OtherEmployeeExpenseEUR | — | — | 229,000Source | 63,000Source | 180,000Source | 147,000Source | — | — | 632,000Source | 603,000Source | — | — |
| OtherOperatingIncomeExpenseEUR | — | — | 87,000Source | -178,000Source | 31,000Source | 58,000Source | 219,000Source | 14,000Source | 1,274,000Source | 1,008,000Source | 544,000Source | 283,000Source |
| PostemploymentBenefitExpenseDefinedBenefitPlansEUR | — | — | — | — | — | — | — | — | — | 190,000Source | 210,000Source | 260,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansEUR | — | — | 69,000Source | 90,000Source | — | — | — | — | 159,000Source | — | — | — |
| ProfitLossAttributableToOwnersOfParentEUR | — | — | -6,240,000Source | -8,762,000Source | — | -13,124,000Source | -12,797,000Source | -4,990,000Source | -90,085,000Source | -59,236,000Source | -43,212,000Source | -31,225,000Source |
| ProfitLossBeforeTaxEUR | — | — | -6,175,000Source | -8,626,000Source | -20,329,000Source | -12,683,000Source | -11,869,000Source | -4,883,000Source | -89,076,000Source | -56,432,000Source | -44,657,000Source | -30,056,000Source |
| ProfitLossFromOperatingActivitiesEUR | — | — | -8,778,000Source | -8,070,000Source | -19,850,000Source | -13,307,000Source | -11,883,000Source | -7,390,000Source | -83,485,000Source | -58,809,000Source | -45,102,000Source | -32,499,000Source |
| ResearchAndDevelopmentExpenseEUR | — | — | 4,221,000Source | 3,517,000Source | 10,059,000Source | 7,472,000Source | 6,605,000Source | 3,470,000Source | 42,824,000Source | 34,325,000Source | 26,651,000Source | 15,861,000Source |
| RevenueFromInterestEUR | — | — | — | — | 513,000Source | 472,000Source | — | — | 1,834,000Source | 2,502,000Source | — | — |
| OtherFinanceCost | — | — | —Source | —Source | — | —Source | —Source | — | — | — | — | — |
Filing attachments
tm2629001d1_ex99-1.htm · 6-K · 2026-11-05
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Third Quarter 2026 Financial and Operating Results Global net revenue was €9.2 million driven by 29% sequential U.S. net revenue growth PMA supplement submitted to the FDA to expand Genio’s U.S. indication to include Complete Concentric Collapse patients Mont-Saint-Guibert, Belgium - November 5, 2026, 10:05 pm CET / 4:05 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops …
Read attachment ↗tm2629001d1_ex99-2.htm · 6-K · 2026-11-05
Exhibit 99.2 INTERIM FINANCIAL REPORT THIRD QUARTER 2026 TABLE OF CONTENTS Interim 3 financial report 1. Business 3 update 2. FINANCIAL HIGHLIGHTS …
Read attachment ↗tm2627823d1_ex99-1.htm · 6-K · 2026-10-20
Exhibit 99.1 REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 U.S. net revenue grows 29% sequentially, driving third quarter global preliminary net revenue of €9.2 million PMA supplement submitted to the FDA to expand Genio’s U.S. indication to Complete Concentric Collapse patients Mont-Saint-Guibert, Belgium - October 19, 2026, 2:00 pm CET / 08:00 am ET - Nyxoah SA (Euronext Brussels/Nasdaq: N…
Read attachment ↗tm2626577d1_ex99-1.htm · 6-K · 2026-09-29
Exhibit 99.1 REGULATED INFORMATION INSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company’s strategic U.S. presence and focus Mont-Saint-Guibert, Belgium - September 28, 2026, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointme…
Read attachment ↗tm2625920d1_ex99-1.htm · 6-K · 2026-09-22
Exhibit 99.1 REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Chief Financial Officer Transition Loïc Moreau, Nyxoah’s President International and former CFO, to serve as interim CFO Company reaffirms full year 2026 financial guidance Mont-Saint-Guibert, Belgium - September 21, 2026, 22:01h CET / 4:01h ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apn…
Read attachment ↗nyxh-20260630xex99d1.htm · 6-K · 2026-08-05
Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium - August 5, 2026, 10:05pm CET / 4:05pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions t…
Read attachment ↗